Alliance Urology Specialists

Protocol Number: FE200486 CS21A, Sponsor: Ferring Pharmaceuticals

	Eligibility Criteria for participation: Histologically proven prostate cancer of all stages in whom endocrine treatment is indicated Completed the FE 200486 CS21 study Not withdrawn/discontinued from the FE 200486 CS21 study No previous surgical castration No GnRH receptor agonist No previous prostatectomy Duration of Study The patients will receive treatment at one-month intervals until all patients are discontinued / withdrawn from the study, degarelix is commercially available, a decision has been taken to end the development of the compound, or the study has been terminated by sponsor or investigator for other reasons. Clinical Research Coordinators: Patricia Edwards, RN (336) 274-1114 ext. 5322 Karen Michael, RN (336) 274-1114 ext. 5328 E-mail address: research@allianceurology.com